These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35070040)

  • 1. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.
    Alqahtani SA; Colombo MG
    World J Gastrointest Oncol; 2021 Dec; 13(12):2038-2049. PubMed ID: 35070040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma.
    Rehman O; Jaferi U; Padda I; Khehra N; Atwal H; Mossabeh D; Bhangu R
    Clin Exp Hepatol; 2021 Sep; 7(3):249-257. PubMed ID: 34712825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
    Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
    Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.
    Personeni N; Pressiani T; Rimassa L
    J Hepatocell Carcinoma; 2019; 6():31-39. PubMed ID: 30775342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
    Tajiri K; Tokimitsu Y; Kawai K; Motofuji Y; Shinno E; Kashii Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
    Anticancer Res; 2022 Dec; 42(12):6007-6018. PubMed ID: 36456142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.